The panel consensus is bearish on Rocket Lab (RKLB), citing execution risk in developing the Neutron rocket, integration risk with the Iridium acquisition, and the challenge of competing with SpaceX's established advantages in reusability, vertical integration, and Starlink scale.
Risk: Execution risk in bringing Neutron to market and integrating the Iridium acquisition
Opportunity: Securing orbital slots and spectrum rights through the Iridium acquisition
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Key Points
- Rocket Lab has fantastic growth potential, at least the same or better than SpaceX.
- It has a lower price-to-sales (P/S) ratio.
- Neither stock looks appetizing right now.
- These 10 stocks could mint the next wave of millionaires ›
Space is the final frontier, and investors are pricing in reaching that frontier …
Read more
Key Points
- Rocket Lab has fantastic growth potential, at least the same or better than SpaceX.
- It has a lower price-to-sales (P/S) ratio.
- Neither stock looks appetizing right now.
- These 10 stocks could mint the next wave of millionaires ›
Space is the final frontier, and investors are pricing in reaching that frontier sooner rather than later. The hottest stock of 2026 is Space Exploration Technologies, which leapfrogged almost every stock in the world to become the eighth most valuable business by market cap after its initial public offering (IPO).
Investors think the future lies with SpaceX and its endeavors in satellite internet and artificial intelligence (AI). But what if there was a cheaper way to invest in the space economy? Enter Rocket Lab (NASDAQ: RKLB). The SpaceX competitor is growing rapidly and could be a much better long-term winner in the stock market.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Here's why I think Rocket Lab will outperform SpaceX stock over the next 10 years.
Betting on growth
Rocket Lab has been a niche player in the space economy in the last five years, but that has not meant it has experienced rapid revenue growth from a small starting place. It has steadily grown the launch cadence of its small Electron rocket, which works with satellite players and the United States government.
Alongside its launch business, Rocket Lab has been organically developing and acquiring capabilities in space systems manufacturing. This includes satellite development, communications, solar arrays, and many other capabilities it can build for third parties and itself. These dual growth engines, which work in tandem to win contracts, help explain why Rocket Lab's revenue has grown by roughly 870% since going public in 2021, and why its backlog is now $2.36 billion, or more than three times its trailing revenue of $769 million.
Long-term, this growth should continue when Rocket Lab debuts its Neutron rocket later this year or in early 2027. The Neutron will help Rocket Lab directly compete with SpaceX for payloads. Second, Rocket Lab will soon close its acquisition of Iridium Communications, which will springboard it into the satellite internet business, directly competing with SpaceX's Starlink. Given this trajectory, I think Rocket Lab could more than 10x its revenue over the next decade to $10 billion.
Cheaper valuation
Another notch in Rocket Lab's belt over SpaceX is the starting valuation. Both businesses are growing quickly, but Rocket Lab actually gets a cheaper starting price-to-sales (P/S) ratio compared to SpaceX at a smaller market cap.
SpaceX has a trailing P/S ratio of 94, while Rocket Lab's is 56. This is likely due to Elon Musk's massive projections for future growth at SpaceX, but, as we all know with Musk, they can take longer to materialize than originally thought. Rocket Lab is no slouch when it comes to product development delays, but it has a smaller market cap at $44 billion vs. SpaceX's $2 trillion, and is also growing like a weed.
Are any space stocks a buy today?
When you look at the growth potential and starting valuation, I think Rocket Lab will outperform SpaceX over the next decade. That does not mean the stock will deliver monster returns for shareholders.
Taking an objective look at valuation paints a darker picture. Rocket Lab currently has a market cap of $44 billion, one that is going to be diluted going forward through consistent share sales. If Rocket Lab's dilution leads to a $50 billion market cap 10 years from now at current prices, that is a 5x multiple compared to my rough $10 billion estimate for revenue.
While investors might think this is cheap, the space business does not come with high margins, and this would only mean the stock is valued at a reasonable multiple 10 years from now, compared to the current share price, or a flat share price. This should make Rocket Lab a stock to avoid right now.
Don’t miss this second chance at a potentially lucrative opportunity
Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this.
On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves:
- Nvidia:if you invested $1,000 when we doubled down in 2009,- you’d have $585,136!*
- Apple:if you invested $1,000 when we doubled down in 2008,- you’d have $65,062!*
- Netflix:if you invested $1,000 when we doubled down in 2004,- you’d have $383,680!*
Right now, we’re issuing “Double Down” alerts for three incredible companies, available when you join Stock Advisor, and there may not be another chance like this anytime soon.
**Stock Advisor returns as of September 27, 2026. *
Brett Schafer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Rocket Lab. The Motley Fool has a disclosure policy.
AI Talk Show
Four leading AI models discuss this article
Opening Takes
“Rocket Lab’s current valuation is detached from its actual cash-flow generation, making it a speculative play rather than a fundamentally sound investment compared to the proven infrastructure of SpaceX.”
The article’s premise that Rocket Lab (RKLB) is a 'cheaper' alternative to SpaceX relies on a flawed valuation framework. Comparing a $44 billion market cap to a $2 trillion behemoth ignores the massive moat SpaceX has built through Starlink’s recurring revenue and the Falcon 9’s unmatched launch reliability. RKLB is currently burning cash to fund the Neutron rocket development, and the article’s assumption of a 10x revenue increase to $10 billion assumes flawless execution in a capital-intensive industry with thin margins. Investors are paying a premium for RKLB’s potential, but they are essentially betting on a 'SpaceX-lite' narrative that ignores the extreme execution risk inherent in orbital launch and satellite manufacturing.
If Rocket Lab successfully captures a significant share of the national security launch market and achieves vertical integration efficiencies that SpaceX cannot replicate due to its sheer scale, the current valuation could be viewed as a bargain relative to its long-term total addressable market.
“RKLB's valuation discount to SpaceX reflects real competitive disadvantages (smaller addressable market, lower margins, execution risk), not a hidden bargain, and the author's own math suggests zero real returns over 10 years.”
The article's core argument—that RKLB's lower P/S ratio (56x vs. SpaceX's 94x) makes it a better 10-year bet—collapses under its own math. The author admits RKLB at $50B market cap with $10B revenue in 2036 implies a flat stock price from today, yet somehow frames this as outperformance. The real issue: space launch is commoditizing (Blue Origin, Chinese competitors), satellite internet margins are brutal (Starlink struggles to profitability), and RKLB's $2.36B backlog sounds impressive until you realize it's only 3x trailing revenue—not exceptional for a capital-intensive business. The Iridium acquisition is also unvetted here; Iridium's legacy satellite network faces obsolescence risk from mega-constellations. SpaceX's 94x P/S reflects Starlink's addressable market (billions of unconnected users); RKLB's 56x may simply reflect lower TAM and execution risk.
If Neutron launches successfully in 2026-27 and wins material government contracts (national security angle), or if the Iridium deal unlocks unexpected synergies in LEO constellation services, RKLB could re-rate sharply and justify current valuations—making the 'flat stock' scenario too pessimistic.
“Rocket Lab's Neutron delays and thin margins make the projected 10x revenue growth far less certain than the article implies, capping any outperformance versus SpaceX.”
The article correctly flags Rocket Lab's 870% revenue growth and $2.36B backlog but underplays execution risk on Neutron, whose first flight is already slipping, and the Iridium acquisition's integration costs. SpaceX maintains decisive advantages in reusability, vertical integration, and Starlink scale that a $44B market-cap rival cannot easily close. At 56x trailing sales with ongoing dilution, RKLB's path to $10B revenue still implies limited upside once margins and competitive reality are modeled. Investors should treat the 10-year outperformance thesis as speculative rather than probable.
If Neutron launches on schedule and wins multiple NSSL contracts while Iridium accelerates cash flow, revenue could hit $8-12B by 2035, compressing the multiple enough to deliver 3-5x returns despite dilution.
“Rocket Lab faces structural execution and funding risks that could prevent it from delivering the scale needed to outperform a much larger, private SpaceX moat.”
The article markets Rocket Lab as a cheaper, faster path into the space economy, citing backlog growth and Neutron/Iridium deals as catalysts. Yet the missing context is material: SpaceX is private, so its size, profitability, and cash flow are opaque, making P/S comparisons dubious. RKLB faces dilution risk to fuel growth, execution risk in bringing Neutron to market, integration risk with Iridium, and margin pressure in a capital-intensive segment. SpaceX’s Starlink and DoD contracts offer a durable, high-margin revenue backbone that RKLB would struggle to match. Capex, program delays, and government cycles could sap revenue visibility, making the optimistic 10x revenue target unlikely.
The strongest counter is that SpaceX’s private scale and integrated ecosystem create a moat RKLB can’t realistically close in a decade; unless RKLB delivers sustained, outsized execution and new high-margin revenue streams, the outperformance thesis is questionable.
The Debate
Responding to Claude
“The Iridium acquisition provides critical spectrum and orbital assets that drastically shorten Rocket Lab's time-to-market for a space-as-a-service platform.”
Claude, your dismissal of the Iridium acquisition as 'legacy risk' misses the strategic value: Rocket Lab isn't buying the hardware, they are buying the constellation's orbital slots, spectrum rights, and established customer base. In the space industry, spectrum is the ultimate moat. By integrating these assets with Neutron, RKLB gains a ready-made platform for space-as-a-service. This isn't about legacy tech; it's about securing the regulatory and infrastructural real estate that SpaceX spent years fighting to obtain.
Responding to Gemini
“Spectrum rights are only valuable if RKLB can monetize them faster than competitors; inheriting Iridium's saturated constellation may be a liability, not a moat.”
Gemini's spectrum-moat argument is compelling but overstates RKLB's leverage. Spectrum rights are valuable only if RKLB can monetize them faster than competitors—and Iridium's legacy constellation is already saturated in LEO. The real question: does RKLB gain exclusive access to high-demand orbital slots, or just inherit maintenance costs? Integration risk remains material. SpaceX didn't 'fight years' for spectrum; they built Starlink from scratch with superior tech. Buying legacy infrastructure isn't the same as building a moat.
Responding to Gemini
“Iridium spectrum rights will require heavy refresh spending that delays RKLB's cash-flow breakeven by multiple years.”
Gemini's spectrum-moat claim ignores that Iridium's slots still demand billions in constellation refresh capex, directly competing with Neutron funding and extending cash burn. Claude flags monetization limits but misses how this stretches RKLB's timeline to free cash flow by several years under continued dilution. The regulatory assets only become a durable edge once they generate high-margin services ahead of Starlink's next spectrum iteration cycle.
Responding to Claude
“Neutron/NSSL timing and Iridium costs push cash flow realization beyond 2028, making the 56x multiple potentially too optimistic.”
Claude's P/S framing misses timing risk. Space launch programs are lumpy; Neutron won’t monetize until DoD/NSSL contracts materialize, which can take years. Iridium integration adds upfront cost and regulatory delay; even 56x sales assumes rapid margin expansion that Street may not grant if capex remains high. If near-term visibility stays poor into 2028, the stock may underperform despite Starlink-scale talk.
Panel Verdict
NEUTRAL Consensus ReachedThe panel consensus is bearish on Rocket Lab (RKLB), citing execution risk in developing the Neutron rocket, integration risk with the Iridium acquisition, and the challenge of competing with SpaceX's established advantages in reusability, vertical integration, and Starlink scale.
Securing orbital slots and spectrum rights through the Iridium acquisition
Execution risk in bringing Neutron to market and integrating the Iridium acquisition
Related News
This is not financial advice. Always do your own research.